NCT01226316
Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 130 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Brain metastases unless asymptomatic, treated & stable
https://ClinicalTrials.gov/show/NCT01226316